Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluating mesothelin as an immunotherapeutic target for endogenous T cells.

Frontiers in immunology·2026
Same author

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Cell reports. Medicine·2026
Same author

See Me, Support Me: A platform for student voice can unlock teachers' support for English language learner students in the entrance to high school.

Cultural diversity & ethnic minority psychology·2026
Same author

Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy.

bioRxiv : the preprint server for biology·2026
Same author

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Nature medicine·2026
Same author

ANTXR1 blockade enhances cardiac function in preclinical models of heart failure.

Nature cardiovascular research·2025

相关实验视频

Updated: Sep 11, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.9K

武装IL-7的二进制CAR T细胞策略来增强对固体瘤的功效.

Alejandro G Torres Chavez1, Mary K McKenna1, Anmol Gupta1

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, United States.

Frontiers in immunology
|August 14, 2025
PubMed
概括

这项研究引入了针对固体瘤的双向化学抗原受体 (CAR) T细胞疗法,增强了IL-7细胞因子的支持. 这种方法改善了T细胞的持久性和抗瘤作用,为难以治疗的癌症提供了一个有希望的策略.

关键词:
在IL-7中,IL-7是最常见的.在IL-7R中,IL-7R是最常见的.一个MUC1一个MUC1这是PSCA的PSCA.通过T细胞治疗治疗.仿制性抗原受体的仿制性抗原受体胰腺癌是一种癌症.固体瘤是一个固体瘤.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

795
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

433

相关实验视频

Last Updated: Sep 11, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

795
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

433

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法对B细胞恶性瘤有希望,但在固体瘤中面临挑战,包括抗原损失,异质性和T细胞持久性差.
  • 目前的策略往往难以同时解决瘤微环境中的抗原多样性和T细胞寿命.

研究的目的:

  • 开发和评估一种用于固体瘤的新型CAR T细胞策略,可以克服抗原异质性并增强T细胞持久性.
  • 为了研究双重向的CAR T细胞系统的有效性,该系统与转基因IL-7细胞因子支持进行了工程设计.

主要方法:

  • 工程T细胞表达独立的CAR,向两个不同的固体瘤抗原:PSCA和MUC1.
  • 在CAR T细胞内内嵌的转基因Interleukin-7 (IL-7) 细胞因子和受体 (IL-7Rα) 表达,以促进局部的持久性和功能.

主要成果:

  • 在胰腺瘤模型中,双向的CAR T细胞策略与IL-7支持显示出卓越的抗瘤功效和持久效果.
  • 与没有IL-7的单向CAR或双向CAR相比,这种增强的二进制方法导致了显著的T细胞扩张和持续的抗瘤活性.
  • 双抗原识别和细胞因子支持的组合有效地解决了瘤异质性,并改善了T细胞的寿命.

结论:

  • 转基因IL-7武装的二进制CAR T细胞代表了对固体瘤的强有力的治疗策略.
  • 这种方法有可能提高CAR T细胞疗法的疗效,挑战固体瘤的适用性.